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number of future HCV related complications, reduce costs and increase the 
number of QALYs experienced.  
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OBJECTIVES: The purpose of this study is to compare the direct cost parameters 
on rheumatoid arthritis (RA) by using two studies in Turkey conducted via 
patient database record system and via expert opinion methodology in 2010. 
METHODS: The data included in this study was collected upon the opinions of 
22 rheumatologists from 53 clinics in Turkey. The other study was completed by 
Turkish Health Insurance Funds Database (THIFD) —1920 patients selected for a 
6-month period. RESULTS: Based on the patient database, 5% of the patients 
were hospitalized and 42% had outpatient visit. According to expert opinion, 
7.2% of the patients were hospitalized and 77.12% had outpatient visit. Patient 
records state that non-COX inhibitors (78%) and immunosuppressants (71%), and 
disease-modifying anti-rheumatic drugs (DMARDs) (11%) of the patients were 
prescribed and biologic DMARDs are not specifically stated. Based on the 
rheumatologists, non-COX inhibitors (34.52%), immunosuppressants (39.76%), 
methotrexate (80.86%), sulfasalazine (31.76%) and biologic DMARDs (17.15%) were 
prescribed. Total annual cost (EUR€2,386) results of the patient database system 
comprised of pharmacy costs (EUR€1,747), outpatient costs (EUR€360), and 
inpatient costs (EUR€252). Annual cost from expert opinion was EUR€2917.03 
with outpatient & inpatient costs (EUR€206.82) and pharmacy and 
prostheses/orthoses cost (EUR€2710.21). CONCLUSIONS: Expert panel 
methodology’s important way to observe the real world practice. It’s observed 
that expert panel and patient database results are in line with each other. Due to 
the distribution of the pharmaceuticals, a difference of only EUR€531.03 was 
found. It can be observed that biologic DMARDs treatments are perceived to be 
prescribed more, however according to patient data, prescribed ratio of biologic 
DMARDs is relatively low. THIFD is used to extract patient costs where patient 
records are used for controlling reimbursement criteria, so some of the data may 
be misleading. Accurate performing of coding is key issue to minimize possible 
bias in use of patient data.  
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OBJECTIVES: The purpose of this study is to compare the direct cost parameters 
on ankylosing spondylitis (AS) by using two studies in Turkey conducted via 
patient database record system and via expert opinion methodology in 2010. 
METHODS: The data included in this study was collected upon the opinions of 22 
rheumatologists from 53 clinics in Turkey. The other study was completed by 
Turkish Health Insurance Funds Database (THIFD) —1920 patients selected for a 
6-month period. RESULTS: Based on the patient database, 7% of patients were 
hospitalized and 46% had at least one outpatient visit. According to expert 
opinion, 8.2% of the patients were hospitalized and 66% had outpatient visit. 
Patient records state that non-COX inhibitors (71%), and disease-modifying anti-
rheumatic drugs (DMARDs) (35%), are prescribed. Based on the rheumatologists, 
non-COX inhibitors (81.37%) and immunosuppressant (7.52%), methotrexate 
(13.21%), sulfasalazine (40.24%), non-steroidal anti-inflammatory drug (81.37%) 
and biologic DMARDs (24.95%) were prescribed. Total annual cost (EUR€4,233) 
results of the patient database comprised of pharmacy costs (EUR€3,760), 
outpatient costs (EUR€297), and inpatient costs (EUR€155). Annual cost from 
expert opinion was EUR€3,565.91, with outpatient and inpatient costs 
(EUR€239.57), and pharmacy and prostheses/orthoses cost (EUR€3,326.33). 
CONCLUSIONS: Expert panel methodology’s important way to observe the real 
world practice. It’s observed that expert panel and patient database results are in 
line with each other. Due to the distribution of the pharmaceuticals, a difference 
of only EUR€239.58 was found. It can be observed that biologic DMARDs 
treatments are perceived to be prescribed more, however according to patient 
data, the prescribed ratio of biologic DMARDs is relatively low. THIFD is used to 
extract patient costs where patient records are used for controlling 
reimbursement criteria so some of the data may be misleading. Accurate 




ALL-CAUSE AND DISEASE-RELATED COSTS ASSOCIATED WITH RECURRENT 
VENOUS THROMBOEMBOLISM  
Lefebvre P1, Laliberté F2, Nutescu E3, Duh MS4, LaMori JC5, Bookhart B5, Olson WH6,  
Dea K2, Hossou Y2, Schein JR5, Kaatz S7 
1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Groupe d'analyse, Ltée, Montréal, QC, Canada, 
3University of Illinois at Chicago, Chicago, IL, USA, 4Analysis Group, Inc., Boston, MA, USA, 
5Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 6Janssen Scientific Affairs, LLC, Titusville, NJ, 
USA, 7Hurley Medical Center, Flint, MI, USA  
OBJECTIVES: To describe the real-world clinical complications associated with 
recurrent venous thromboembolism (VTE) and to quantify the incremental direct 
all-cause and disease-related health care costs associated with recurrent VTE. 
METHODS: An analysis of health care insurance claims from the Ingenix 
IMPACTdatabase was conducted. Between January 2004 and September 2008, 
subjects aged ≥18 years on the date of first recurrent VTE diagnosis requiring 
hospitalization (index recurrent deep vein thrombosis [DVT], pulmonary 
embolism [PE], or both) with ≥12 months of baseline observation prior to the 
index recurrent VTE were matched 1:1 with control VTE patients without 
recurrence, based on exact matching factors and propensity scores. The 
proportion of patients with post-thrombotic syndrome (PTS) was calculated for 
up to 1 year and compared between the two groups. All-cause health care and 
disease-related costs (thrombocytopenia, superficial venous thrombosis, venous 
ulcer, pulmonary hypertension, stasis dermatitis, and venous insufficiency) per 
patient per year (PPPY) were also calculated and compared between the two 
groups. RESULTS: The recurrent VTE and VTE control cohorts (8,001 subjects 
each) were well matched for age, gender, comorbidities, VTE risk factors 
distributions, and baseline health care costs. The risk of PTS was 18.1% for the 
recurrent VTE cohort and 6.8% for the no recurrent VTE cohort (risk ratio: 2.7  
[2.4 - 2.9]). Patients with recurrent VTE had significantly higher average PPPY all-
cause costs compared to control patients (mean: $86,744 versus $37,525, cost 
difference=$49,219; 95% CI=46,253–51,989). Corresponding disease-related health 
care costs PPPY were also significantly higher for the recurrent VTE group (mean 
$11,120 versus $1,262, cost difference=$9,858, 95% CI=$9,081-$10,476) and 
represented 20.0% ($9,858 of $49,219) of the all-cause cost difference between the 
two groups. CONCLUSIONS: In this large matched-cohort study, recurrent VTE 
patients had a significantly higher risk of PTS compared to VTE control patients 
and were also associated with a significant health care cost burden.  
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OBJECTIVES: The phosphate binders sevelamer hydrochloride (SH) and 
lanthanum carbonate (LC) will be included in the Medicare bundled 
reimbursement scheme from 2016. The aim of this study was to evaluate the 
cost implications of switching patients from SH to LC monotherapy. METHODS: 
A post hoc analysis of the cost implications of switching from SH to LC 
monotherapy was performed using data from a 16 week, phase 4, real-world 
clinical study (n = 953). Daily LC doses were titrated to maintain the level of 
phosphate control achieved with SH at baseline. Costs of mean daily drug doses 
were calculated using the average wholesale price (LC 1000 mg: $8.82; SH 800 mg: 
$3.71). Analyses were performed by baseline SH dose group (per mean daily dose) 
and by real clinical doses of SH and LC. RESULTS: Mean (SD) serum phosphate 
levels were 5.88 (1.69) mg/dL at baseline and 5.93 (1.85) mg/dL after 16 weeks of 
LC treatment. Mean doses and associated costs by baseline SH dose group were 
as follows: SH 2400–4800 mg/day: 4051 mg/day ($18.79/day) versus LC 2445.4 
mg/day ($21.57/day); SH >4800–7200 mg/day: 7047 mg/day ($32.68/day) versus LC 
2823 mg/day ($24.90/day); SH >7200–9600 mg/day: 9253 mg/day ($42.91/day) 
versus LC 3018 mg/day ($26.62/day); SH >9600 mg/day: 13 150 mg/day 
($60.98/day) versus LC 3156 mg/day ($27.84/day). Analysis by real clinical doses 
revealed that LC 3000 mg/day ($26.46/day) is less costly than SH 6400 mg/day 
($29.68/day) and 7200 mg/day ($33.39/day), but not SH 5600 mg/day ($25.97/day). 
At baseline, 65% of patients were receiving SH ≥6400 mg/day. CONCLUSIONS: 
Our analysis showed that LC is more cost-effective than SH in patients taking SH 
≥6400 mg/day (65% of patients at baseline). Switching these patients to LC 3000 
mg/day would offer cost savings, a reduced daily pill burden (3 vs >8/day) and 
effective maintenance of phosphate control.  
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OBJECTIVES: To evaluate the cost-effectiveness of prescribing branded 
Taxotere®compared to its generic counterpart docetaxel for patients diagnosed 
with breast cancer in the UK NHS. METHODS: A previously published decision 
tree model was populated and developed with the Vial et. al. and Brown et. al. 
trial data to assess the cost-effectiveness of using branded Taxotere®versus its 
generic counterpart docetaxel from the UK NHS perspective. RESULTS: If the 
branded Taxotere® was promoted as the first-line therapy, it would cost the UK 
NHS £411.54 per vial per patient with 0.434 QALY gain compared to £412.98 with 
0.418 QALY gain if the generic docetaxel was promoted instead and failed the 
therapy. Although the acquisition cost of docetaxel is more than 50% less than 
that of Taxotere®, promoting the generic docetaxel based on its lower acquisition 
cost, only, would result in increasing the total health care cost compared to 
Taxotere®. CONCLUSIONS: Based on the decision tree model generated in this 
study, promoting the branded Taxotere® is more cost-effective compared to its 
generic counterpart docetaxel. This should be considered for implementation in 
practice and for future guidelines.  
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OBJECTIVES: Previous studies have documented the impact of otitis media 
among children, but recent estimates of cost of otitis media (OM) among children 
in the United States (US) are not available. The objective of this study was to 
estimate the incremental direct medical expenditures of treating OM among 
children in the US. METHODS: Retrospective analysis was conducted using the 
2010 Medical Expenditure Panel Survey (MEPS) data. Among all children (age<18 
years; n=8,710), those with OM were identified using International Classification 
